-- 美国基准股指盘中多数下跌,科技股承压,此前有报道称OpenAI未能达到销售目标,而油价上涨。 周二午盘过后,纳斯达克综合指数下跌1.3%,报24,575.3点;标普500指数下跌0.7%,报7,127点;道琼斯工业平均指数上涨0.2%,报49,268.9点。各板块中,科技板块跌幅最大,下跌1.9%,而能源板块领涨。 科技巨头英伟达(NVDA)盘中下跌3%,成为道琼斯指数中表现最差的股票。博通(AVGO)、AMD、甲骨文(ORCL)和英特尔(INTC)股价也出现下跌。微软(MSFT)则上涨0.7%。 据《华尔街日报》援引匿名消息人士报道,OpenAI近期未能实现其新增用户和营收目标。 “《华尔街日报》部分地将此报道解读为对数据中心支出的担忧,认为OpenAI投资过度,而销售却在放缓,”Wedbush Securities分析师Matt Bryson在发给的一份电子邮件报告中写道。“我们认为基础设施需求依然强劲,这在很大程度上是由人工智能(AI)应用增长所驱动,从而为半导体和组件供应商创造了广泛的需求驱动力。” 在其他公司新闻方面,可口可乐(KO)周二上调了全年盈利增长预期,此前这家饮料巨头公布的第一财季业绩超出市场预期,这得益于价格和销量的增长。该股盘中上涨6.3%,成为道琼斯指数中表现最佳的股票,也是标普500指数中涨幅第二大的股票。 Spotify Technology(SPOT)股价下跌13%,此前这家音频流媒体平台的付费用户增长和前景令投资者失望。 西德克萨斯中质原油上涨3.6%,至每桶99.84美元;布伦特原油上涨2.8%,至每桶111.34美元。 据《华尔街日报》援引美国官员的话报道,美国总统唐纳德·特朗普和国家安全官员对伊朗提出的开放霍尔木兹海峡并推迟铀浓缩谈判的新提议持怀疑态度。 在世界其他地区,阿拉伯联合酋长国于周五决定退出石油输出国组织(欧佩克)。Rystad Energy表示,此举将使该组织“结构性削弱”。 Rystad在一份报告中指出,阿联酋是少数几个拥有剩余产能的欧佩克成员国之一,其他成员国还包括沙特阿拉伯。欧佩克采用产量配额制度来稳定全球石油市场。 “因此,它的退出削弱了欧佩克管理市场能力的核心支柱之一,”Rystad地缘政治分析主管豪尔赫·莱昂写道。 美联储货币政策委员会召开为期两天的利率会议,将于周三公布决议。据芝加哥商品交易所(CME)的FedWatch工具显示,市场普遍预期美联储将连续第三次维持基准贷款利率不变。 美国国债收益率盘中走高,10年期国债收益率上涨1.8个基点至4.36%,2年期国债收益率上涨4.1个基点至3.84%。 黄金价格下跌2.1%,至每盎司4593.10美元;白银价格下跌2.8%,至每盎司72.95美元。
Related Articles
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%